Aurobindo Pharma Limited – Corporate Announcement (AUROPHARMA / 524804)

Introduction

On 12 September 2026, Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804) filed a disclosure with the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) regarding a related‑party acquisition involving its step‑down subsidiary, A1 Biochem Labs (India) Private Limited.

Key Highlights of the Acquisition

Target Entity

• Name: A1 Biochem USA Inc
• Incorporation: 27 August 2026, United States
• Industry: Pharmaceuticals – Contract Research and Development (CR&D) services
• Turnover: Not applicable (company has not commenced business)

Transaction Details

• Acquirer: A1 Biochem Labs (India) Private Limited (step‑down subsidiary of Aurobindo Pharma)
• Nature of Consideration: Cash – subscription to the entire share capital
• Shares Subscribed: 10,000 equity shares at USD 100 each (total USD 1,000,000)
• Shareholding Acquired: 100 % of A1 Biochem USA Inc
• Purpose: To enable the subsidiary to undertake CR&D services as part of the broader A1 Biochem Group acquisition disclosed on 23 July 2026

Related‑Party Status

• A1 Biochem USA Inc is a wholly‑owned subsidiary of A1 Biochem Labs (India) Private Limited.
• A1 Biochem Labs (India) Private Limited is itself a subsidiary of Apitoria Pharma Private Limited, which is wholly owned by Aurobindo Pharma.
• Consequently, the transaction is a related‑party transaction.
• Promoters and promoter group of Aurobindo Pharma have no interest in the transaction; it is being executed at arm’s length.

Regulatory & Compliance Aspects

• Governmental/Regulatory Approvals: None required for this acquisition.
• Completion Timeline: Not applicable (subscription completed on 11 September 2026).

Strategic Rationale

• The acquisition aligns with Aurobindo Pharma’s strategy to expand its contract research and development capabilities in the United States.
• It builds on the earlier acquisition of the A1 Biochem Group announced on 23 July 2026, further integrating the group’s global R&D footprint.

Attachments

• Annexure A: Detailed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (included in the filing).

Prepared for investors based solely on the information disclosed in the corporate announcement dated 12 September 2026.